<?xml version='1.0' encoding='utf8' standalone='yes'?>
<collection><document><id>7025910</id><passage><infon key="name_3">surname:Kim;given-names:Moon Jung</infon><infon key="name_2">surname:Shin;given-names:Hyun-Young</infon><infon key="name_1">surname:Jeon;given-names:Seunghyun</infon><infon key="article-id_pmid">32056407</infon><infon key="name_0">surname:Lim;given-names:Jaegyun</infon><infon key="issue">6</infon><infon key="year">2020</infon><infon key="article-id_pmc">7025910</infon><infon key="article-id_doi">10.3346/jkms.2020.35.e79</infon><infon key="type">front</infon><infon key="elocation-id">e79</infon><infon key="volume">35</infon><infon key="license">This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</infon><infon key="section_type">TITLE</infon><infon key="journal">J Korean Med Sci. 2020 Feb 17;35(6):e79. doi: 10.3346/jkms.2020.35.e79.</infon><infon key="kwd">Coronavirus COVID-19 Pneumonia Tertiary Infection Viral Load Real-Time Reverse-Transcriptase Polymerase Chain Reaction</infon><infon key="name_9">surname:Park;given-names:Sang-Joon</infon><infon key="name_8">surname:Lee;given-names:Baeckseung</infon><infon key="name_7">surname:Kang;given-names:Yu Min</infon><infon key="name_6">surname:Choe;given-names:Kang-Won</infon><infon key="name_5">surname:Lee;given-names:Wang Jun</infon><infon key="name_4">surname:Seong;given-names:Yu Min</infon><infon key="authors">Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, Choe KW, Kang YM, Lee B, Park SJ</infon><offset>0</offset><text>Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>209</offset><text>Since mid-December of 2019, coronavirus disease 2019 (COVID-19) has been spreading from Wuhan, China. The confirmed COVID-19 patients in South Korea are those who came from or visited China. As secondary transmissions have occurred and the speed of transmission is accelerating, there are rising concerns about community infections. The 54-year old male is the third patient diagnosed with COVID-19 in Korea. He is a worker for a clothing business and had mild respiratory symptoms and intermittent fever in the beginning of hospitalization, and pneumonia symptoms on chest computerized tomography scan on day 6 of admission. This patient caused one case of secondary transmission and three cases of tertiary transmission. Hereby, we report the clinical findings of the index patient who was the first to cause tertiary transmission outside China. Interestingly, after lopinavir/ritonavir (Kaletra, AbbVie) was administered, beta-coronavirus viral loads significantly decreased and no or little coronavirus titers were observed.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1238</offset><text>Graphical Abstract</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1257</offset><text>A 54-year-old Korean man living in Wuhan, China entered Korea on January 20, 2020 and felt the first symptoms of chills and muscle pain on January 22. After contacting a public health center on January 25, he was isolated in a negative pressure room at Myongji Hospital and confirmed to have COVID-19 on January 26.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1573</offset><text>At that time the initial confirmation of COVID-19 was made by pan-coronavirus conventional polymerase chain reaction assay and sequencing of the polymerase chain reaction (PCR) amplicons using a throat swab.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1781</offset><text>The index patient transmitted the virus to his friend (patient A) at a restaurant on the 1st day of the symptoms. And then patient A (confirmed on January 30, 2020) transmitted COVID-19 to his spouse and son (confirmed on January 31, 2020), and a church colleague (confirmed on February 6, 2020). Those were the first cases of tertiary transmission of COVID-19 outside China.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2157</offset><text>The index patient was a clothing worker at the Wuhan Fashion Center, with a height of 193 cm and weight of 96 kg (body mass index, 25.7), and had no major illness. He denied any smoking and drinking history. On admission day, he had no respiratory symptoms and blood pressure of 152/93 mmHg, pulse rate of 73 beats per minute, respiratory rate of 20 breaths per minute, and a body temperature of 37.0 C. On physical examination, no pharyngeal injection, clear lung sounds, and no haziness on chest X-ray were observed. Tests for Leptospira, Hantan virus, Tsutsugamushi, Malaria, M tuberculosis, human immunodeficiency virus (HIV) Ag/Ab, and venereal disease research laboratory (VDRL) test were all negative.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2867</offset><text>He developed fever and dry cough on days 5 and 7 of illness, respectively, but he had no serious respiratory symptoms such as shortness of breath, productive sputum or chest pain. Small consolidation in right upper lobe and ground-glass opacities in both lower lobes were observed on high-resolution computed tomography scan (Figs. 1 and 2, Table 1).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3218</offset><text>The initial viral load could not be measured because real-time PCR was not available when the patient was diagnosed. So we measured viral loads using quantitative reverse transcription (RT)-PCR since Jan. 31, 2020. Viral RNA was extracted from the sputum using QIAamp viral RNA mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. All quantitative real-time PCR amplifications were performed using Quantstudio 1 (Applied Biosystems, Foster City, CA, USA) and PowerCheck  SARS-CoV-2 Real-Time PCR kit (KogeneBiotech, Seoul, Korea).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3779</offset><text>There were some reports about lopinavir/ritonavir (Kaletra, AbbVie) for the treatment of COVID-19. Lopinavir/ritonavir was started from the hospital day 8 (day 10 of illness); 2 tablets (lopinavir 200 mg/ritonavir 50 mg) were given per oral bid. Interestingly, from the next day of lopinavir/ritonavir administration, beta-coronavirus viral load started to decrease and no detectable or little coronavirus titers have been observed since then (Fig. 2 and Supplementary Fig. 1).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4257</offset><text>It is possible that the decreased load of SARS-CoV-2 resulted from the natural course of the healing process rather than administration of lopinavir/ritonavir, or both. Therefore, more data need to be collected to figure out the direct effect of lopinavir/ritonavir on treatment with COVID-19.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4551</offset><text>The patient also complained of psychiatric symptoms such as depression, insomnia and suicidal thoughts after isolation. The patient experienced stress regarding people's reactions from the media reports about the COVID-19 patients. In addition, despite mild symptoms of COVID-19 in his case, isolation in the negative pressure room during treatment might be one of the reasons provoking psychological symptoms. Counseling and related medications were provided under the consult of a psychiatrist.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5048</offset><text>This case shows that the COVID-19 may induce relatively mild symptoms and a patient can recover when early diagnosis of pneumonia was made. When lopinavir/ritonavir was used, we found reduced viral loads and improved clinical symptoms during the treatment. So lopinavir/ritonavir can be recommended to relatively high-risk groups of COVID-19 pneumonia (elderly patients or patients with underlying diseases) from the early stage. But we need more evidence to prove the clinical efficacy of lopinavir/ritonavir based on well controlled clinical trials.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5600</offset><text>The images are published under agreement of the patient.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>5657</offset><text>Ethics statement</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5674</offset><text>Myongji Hospital Institutional Review Board (IRB) approved this study (No. IRB 2020-01-027) and written informed consent was given by the patient.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">footnote</infon><offset>5821</offset><text>Disclosure: The authors have no potential conflicts of interest to disclose.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">footnote</infon><offset>5898</offset><text>Conceptualization: Lim J.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">footnote</infon><offset>5924</offset><text>Data curation: Kim MJ, Lee B, Shin HY, Seong YM.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">footnote</infon><offset>5973</offset><text>Formal analysis: Jeon S, Kim MJ, Shin HY, Lee B.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">footnote</infon><offset>6022</offset><text>Methodology: Lee B.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">footnote</infon><offset>6042</offset><text>Project administration: Park SJ.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">footnote</infon><offset>6075</offset><text>Supervision: Lee WJ, Choe KW.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">footnote</infon><offset>6105</offset><text>Validation: Lee WJ.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">footnote</infon><offset>6125</offset><text>Writing - original draft: Park SJ.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">footnote</infon><offset>6160</offset><text>Writing - review &amp; editing: Choe KW, Kang YM.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">footnote</infon><offset>6206</offset><text>Author Contributions:  </text></passage><passage><infon key="name_3">surname:Oh;given-names:KJ</infon><infon key="name_2">surname:Oh;given-names:Y</infon><infon key="name_1">surname:Choe;given-names:PG</infon><infon key="name_0">surname:Kim;given-names:JY</infon><infon key="issue">5</infon><infon key="pub-id_pmid">32030925</infon><infon key="year">2020</infon><infon key="source">J Korean Med Sci</infon><infon key="type">ref</infon><infon key="elocation-id">e61</infon><infon key="volume">35</infon><infon key="section_type">REF</infon><infon key="name_5">surname:Park;given-names:SJ</infon><infon key="name_4">surname:Kim;given-names:J</infon><offset>6230</offset><text>The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures</text></passage><passage><infon key="name_3">surname:Batty;given-names:GD</infon><infon key="volume">76</infon><infon key="name_2">surname:Stamatakis;given-names:E</infon><infon key="name_1">surname:Kivimaki;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Hamer;given-names:M</infon><infon key="fpage">280</infon><infon key="pub-id_pmid">30579940</infon><infon key="year">2019</infon><infon key="source">Brain Behav Immun</infon><infon key="type">ref</infon><infon key="lpage">283</infon><offset>6378</offset><text>Psychological distress and infectious disease mortality in the general population</text></passage><passage><infon key="name_3">surname:Wang;given-names:X</infon><infon key="name_2">surname:Wu;given-names:P</infon><infon key="name_1">surname:Guan;given-names:X</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Li;given-names:Q</infon><infon key="pub-id_doi">10.1056/NEJMoa2001316</infon><infon key="year">2020</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="name_5">surname:Tong;given-names:Y</infon><infon key="name_4">surname:Zhou;given-names:L</infon><offset>6460</offset><text>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</text></passage><passage><infon key="name_3">surname:Bretzel;given-names:G</infon><infon key="name_2">surname:Sothmann;given-names:P</infon><infon key="name_1">surname:Schunk;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Rothe;given-names:C</infon><infon key="pub-id_doi">10.1056/NEJMc2001468</infon><infon key="year">2020</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="name_5">surname:Wallrauch;given-names:C</infon><infon key="name_4">surname:Froeschl;given-names:G</infon><offset>6545</offset><text>Transmission of 2019-nCoV Infection from an asymptomatic contact in Germany</text></passage><passage><infon key="name_3">surname:Xie;given-names:L</infon><infon key="name_2">surname:Wei;given-names:L</infon><infon key="name_1">surname:Lin;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Chang;given-names:D</infon><infon key="pub-id_doi">10.1001/jama.2020.1623</infon><infon key="year">2020</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="name_5">surname:Dela Cruz;given-names:CS</infon><infon key="name_4">surname:Zhu;given-names:G</infon><offset>6621</offset><text>Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>6739</offset><text>SUPPLEMENTARY MATERIAL</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">jkms-35-e79-g001.jpg</infon><infon key="id">F1</infon><infon key="type">fig_title_caption</infon><offset>6762</offset><text>Radiologic findings of the patient.</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">jkms-35-e79-g001.jpg</infon><infon key="id">F1</infon><infon key="type">fig_caption</infon><offset>6798</offset><text>(A) Chest X-ray of illness day 3, hospital day 1. (B) Chest X-ray of illness day 9, hospital day 7. (C) Chest X-ray of illness day 15, hospital day 13. (D) HRCT scan of illness day 9, hospital day 7. (E) HRCT scan of illness day 15, hospital day 13.</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">jkms-35-e79-g001.jpg</infon><infon key="id">F1</infon><infon key="type">fig_caption</infon><offset>7048</offset><text>AP(P) = Anteroposterior (Portable X-ray), HRCT = high-resolution computed tomography.</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">jkms-35-e79-g002.jpg</infon><infon key="id">F2</infon><infon key="type">fig_title_caption</infon><offset>7134</offset><text>Clinical course, treatment and viral load of the patient.</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">jkms-35-e79-g002.jpg</infon><infon key="id">F2</infon><infon key="type">fig_caption</infon><offset>7192</offset><text>RdRP = RNA-dependent RNA polymerase, Posi = positive, Nega = negative, UD = undeteced, Ct = cycle threshold.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="type">table</infon><offset>7301</offset><text>Variables Illness day 3 (HD 1) Illness day 6 (HD 4) Illness day 7 (HD 5) Illness day 8 (HD 6) Illness day 10 (HD 8) Illness day 12 (HD 10) Illness day 14 (HD 12) Illness day 16 (HD 14) White blood cell count, x103/microL 7,200 5,800 5,200 6,700 6,000 6,700 8,600 9,100 Segment neutrophil, % 59.0 64.2 50.3 69.3 58.8 55.5 63.1 63.0 Lymphocyte, % 28.5 24.0 36.5 19.1 30.9 29.4 24.4 24.9 Monocyte, % 11.5 11.0 11.6 10.7 9.2 13.5 10.9 10.2 Eosinophil, % 0.6 0.3 1.0 0.6 0.8 1.3 1.3 1.5 Hemoglobin, g/dL 16.3 15.4 16.1 15.3 15.2 14.9 14.2 13.9 Platelets, x103/microL 301 176 212 225 229 287 358 507 Glucose, mg/dL 97 114 - - - - - 103 BUN, mg/dL 13.0 7.0 10.1 9.1 9.6 7.9 6.3 8.1 Creatinine, mg/dL 1.0 0.8 1.2 0.8 1.0 0.8 0.8 0.9 Total bilirubin, mg/dL 0.50 0.47 - 0.35 0.61 0.74 0.85 1.09 AST, U/L 27 31 - 22 127 54 19 17 ALT, U/L 29 37 - 29 106 83 45 30 Uric acid, mg/dL 8.6 7.0 - - - - - - CK, U/L - 43 - - - 31 30 28 ALP, U/L - 62 - - - 140 113 95 LDH, U/L - 332 - - - - 351 329 Sodium, mmol/L 138 135 138 137 138 138 138 139 Potassium, mmol/L 4.3 4.1 4.8 4.2 4.2 4.3 4.2 4.3 Chloride, mmol/L 104 104 105 104 102 103 103 103 Total protein, g/dL 7.4 6.4 6.8 6.3 6.3 6.4 6.3 6.5 Albumin, g/dL 4.5 3.9 4.1 3.8 3.8 3.8 3.7 3.7 ESR, mm/hr 26 27 - - 66 - - 82 CRP, mg/dL 0.43 1.23 - 4.51 10.94 9.11 11.20 3.60 Pro-Calcitonin, ng/mL - 0.06 - - - - - - PT, sec 12.5 12.9 - - 13.2 13.1 13.6 13.6 PT INR 0.96 1.00 - - 1.03 1.02 1.07 1.07 aPTT, sec 40.4 38.5 - - 38.8 38.0 40.1 40.7 D-dimer, microg/mL (FEU) - 0.28 - - - - 1.22 - </text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="type">table_title_caption</infon><offset>8820</offset><text>Serial laboratory results of the patient</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="type">table_foot</infon><offset>8861</offset><text>HD = hospital day, AST = aspartate aminotransferase, ALT = alanine aminotransferase, CK = creatine kinase, ALP = alkaline phosphatase, LDH = lactate dehydrogenase, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, PT = prothrombin time, INR = international normalized ratio, aPTT = activated partial thromboplastin time, FEU = fibrinogen equivalent units.</text></passage></document>
</collection>